Good Evening Market Enthusiast,
We don’t normally circle back to the same company this fast, but this one is different.
The last time we featured this name, it ripped over 15% intraday and caught shorts leaning the wrong way.
Now we’re back.
Not months later. Not next quarter.
Now.
Because something is setting up
again... and this time the timing may be even more important.
Here’s what changed:
• Phase 3 is officially underway
• FDA Fast Track is active
• First and only medication of its kind in development
• Targeting a $50B global immunotherapy market
But here’s the part no one is talking about…
It’s the end of the month.
And while there’s no forced expiration, institutional fund managers do have
monthly reporting requirements.
They don’t like showing risky, underwater shorts on their books.
As the calendar flips, big money often scrambles to clean house.
We call it the Monthly Exodus.
When shorts quietly cover — not because they want to…
But because they don’t want their supporters seeing red.
Last time we highlighted this company, the move was
fast.
If pressure builds into month-end again, it could get interesting.
Tomorrow at 9:30AM EST we release the full breakdown.
If you wait for confirmation, you’ll probably be chasing.
Be early.
Max Masters
Co-founder, Market Tips Newsletter
